US health authorities take on the first pharmaceutical tablets to treat 'postpartum depression'

The United States has adopted the “Zuranolone” to become the first oral pill that treats postpartum depression. The US Food and Drug Administration has announced its approval to use the new drug as it will be sold in the commercial name “Zurzuvae”, which according to the American CNN Network will be taken once a day. Postpartum depression is a serious mental illness that affects one of the 7 new mothers after the situation. “A serious life is likely to threaten. “” The women with sadness, a sense of guilt and the concerns of the lack of value, “Versioni said, adding that” the matter can sometimes achieve the thinking of self -warm or children. ” Versioni explained that this type of depression can affect the relationship between the mother and the baby, and that it can also affect the child’s physical and emotional growth. She was of the opinion that “achieving an oral drug would be a useful option for many women to deal with extremist and sometimes threatening feelings.” Side effects and the US Food and Drug Administration have warned that the new drug may affect a person’s ability to carry out activities, and that patients recommend not managing or managing at least 12 hours after using the medicine. The administration said that the side effects of the new drug are sleepy, dizziness, diarrhea, exhaustion, nasopharynxitis (regular cold) and urinary tract infections. She also spurred effective contraceptive methods while using the drug, and a week after taking it, a habit of ‘CNN’. Women with severe depression after birth suffer from suicide, as mothers of mothers caused by suicide represent about 20% of total death after birth. In the United States, it is estimated that more than 400,000 children are born annually for depression mothers. According to the National Institute of Mental Health, depression can continue for months or even years if left untreated. Also read: